Cargando…
SURG-07. The impact of early targeted therapy on the neurosurgical approach to pediatric low-grade glioma
We report two cases of pediatric low-grade glioma (pLGG) treated with vemurafenib, an oral BRAF-inhibitor: a 12-year-old girl with involvement of basal ganglia, hypothalamus, and diencephalic junction; a 3-year-old boy, with an optic pathway/hypothalamic glioma extending along the left optic tract a...
Autores principales: | Piatelli, Gianluca, Pavanello, Marco, Piccolo, Gianluca, Rossi, Andrea, Garrè, Maria Luisa, De Marco, Patrizia, Iurilli, Valentina, Antonelli, Manila, Gaggero, Gabriele, Caruggi, Samuele, Verrico, Antonio, Crocco, Marco, Milanaccio, Claudia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165303/ http://dx.doi.org/10.1093/neuonc/noac079.525 |
Ejemplares similares
-
Early molecular diagnosis of BRAF status drives the neurosurgical management in BRAF V600E-mutant pediatric low-grade gliomas: a case report
por: Piccolo, Gianluca, et al.
Publicado: (2022) -
LGG-34. Nephrological impact of BRAF inhibitors in a pediatric population of central nervous system tumors: a single institution experience
por: Verrico, Antonio, et al.
Publicado: (2022) -
LGG-40. Growth hormone replacement in children on therapy with Vemurafenib for Low Grade Glioma
por: Verrico, Antonio, et al.
Publicado: (2022) -
Dyslipidemia in Children Treated with a BRAF Inhibitor for Low-Grade Gliomas: A New Side Effect?
por: Crocco, Marco, et al.
Publicado: (2022) -
LGG-35. Dyslipidemia in children treated with BRAF inhibitors for brain tumor, a new side effect? A single center retrospective study
por: Crocco, Marco, et al.
Publicado: (2022)